HSR25-159: Real-World Effectiveness of First-Line Osimertinib for Patients in the US With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer Who Were Eligible for Medicare
"HSR25-159: Real-World Effectiveness of First-Line Osimertinib for Patients in the US With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer Who Were Eligible for Medicare" published on 28 Mar 2025 by National Comprehensive Cancer Network.
Authors
- Yan Kwan Lau (ORCID: https://orcid.org/0000-0002-1612-9912)
- R.J-B. Salomonsen
- Pritesh S. Karia (ORCID: https://orcid.org/0000-0001-6440-9452)
- Darren Thomas (ORCID: https://orcid.org/0000-0003-1559-7180)
- Rahul Shenolikar
Institutions
- AstraZeneca (United Kingdom) (GB)
- AstraZeneca (United States) (US)
Publication Details
- Journal
- Journal of the National Comprehensive Cancer Network
- Published
- 2025-03-28
- DOI
- https://doi.org/10.6004/jnccn.2024.7278
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00